Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences Inc (NASDAQ: ANIX) is a clinical-stage biotechnology company advancing novel immunotherapies and vaccines for cancer treatment and prevention. This page provides investors and industry stakeholders with timely updates on ANIX’s oncology innovations, including clinical trial progress, strategic collaborations, and therapeutic breakthroughs.
Access the latest press releases and news covering ANIX’s CAR-T programs targeting ovarian cancer, vaccine development for breast cancer, and partnerships with leading research institutions. Content spans earnings updates, clinical milestones, patent developments, and analysis of emerging technologies like CER-T (chimeric endocrine receptor T-cell) therapy.
Bookmark this page to stay informed about ANIX’s progress in addressing high-need oncology areas through its focused pipeline. Check regularly for authoritative updates on trials, regulatory filings, and scientific advancements directly from the company and verified sources.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has initiated animal testing for two proprietary compounds that exhibited potential in in vitro studies against COVID-19. CEO Dr. Amit Kumar stated that these compounds will soon be compared to Remdesivir, the only FDA-approved antiviral for COVID-19. The company anticipates completing this proof of concept study within weeks. The compounds target key enzymes of the virus, potentially remaining effective against emerging variants. Anixa aims for future human clinical trials following successful animal testing.
Anixa Biosciences, a biotechnology firm focused on cancer and infectious disease treatments, announced that CEO Dr. Amit Kumar will present at B. Riley's Inaugural Oncology Investor Conference on January 20-21, 2021. Dr. Kumar will participate in a fireside chat to discuss the company's recent achievements and future milestones. The presentation, scheduled for January 21 at 10:30 a.m. PST, will be accessible via live webcast for registered attendees. Anixa's innovative portfolio includes cancer immunotherapy and vaccines for breast and ovarian cancer. More details can be found on Anixa's website.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm specializing in cancer and infectious disease solutions, will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021.
CEO Dr. Amit Kumar will discuss key company updates, including FDA approval for human clinical trials of a breast cancer vaccine and advancements in COVID-19 and CAR-T ovarian cancer treatments.
The presentation will be available on-demand starting at 6:00 a.m. ET on January 11, with a 90-day archive accessible thereafter.
Anixa Biosciences (NASDAQ: ANIX) announced FDA clearance for its Investigational New Drug (IND) application for a breast cancer vaccine developed by Cleveland Clinic's Dr. Vincent Tuohy. This innovative vaccine targets the alpha-lactalbumin protein, which is expressed during pregnancy and lactation, aiming to destroy cancer cells before they develop. The initial clinical focus is on Triple Negative Breast Cancer, which is particularly deadly. Funded by the U.S. Department of Defense, this promising trial marks a significant milestone towards the prevention of breast cancer.
Anixa Biosciences, Inc. (NASDAQ: ANIX) reported a breakthrough in its COVID-19 therapeutic program, revealing that its lead compound shows comparable potency to remdesivir, a currently approved antiviral. The compound targets the SARS-CoV-2 enzyme NSP-15, essential for viral replication. Future plans include enhancing the compound's potency and conducting in vivo animal studies. Anixa aims to deliver an orally administered treatment for COVID-19 that could be taken in outpatient settings, addressing a significant gap in current treatment options.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has entered a license agreement with Cleveland Clinic for exclusive rights to develop an innovative ovarian cancer vaccine technology. This vaccine targets anti-mullerian hormone receptor 2 (AMHR2-ED), which reappears in cancerous cells and is seen as a promising target for prevention. Dr. Vincent Tuohy from Cleveland Clinic has been working on this project, aiming to prevent ovarian cancer through immunization. Anixa is also collaborating on a breast cancer vaccine and seeks to enhance its immuno-oncology portfolio.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the filing of an IND application for a prophylactic breast cancer vaccine with the FDA. Developed in collaboration with a Cleveland Clinic research team, led by Dr. Vincent Tuohy, this innovative vaccine targets the protein alpha-lactalbumin, which re-emerges in breast cancer cases. Early animal studies demonstrate significant potential for preventing breast cancer. Funded by the U.S. Department of Defense, two Phase 1 clinical trials are planned. This vaccine aims to change breast cancer prevention approaches, particularly for women diagnosed with high-risk early-stage TNBC.
Anixa Biosciences, Inc. (NASDAQ: ANIX) will host a conference call on November 2, 2020, at 1:30 p.m. Pacific / 4:30 p.m. Eastern. CEO Dr. Amit Kumar will discuss key developments, including the upcoming Investigational New Drug (IND) application for a breast cancer vaccine in partnership with the Cleveland Clinic, progress on CAR-T therapy for ovarian cancer with Moffitt Cancer Center, and updates on COVID-19 therapy. Investors can join via phone at (877) 876-9174 (Conference ID: Anixa) or through a webcast on the company’s website.
Anixa Biosciences (NASDAQ: ANIX) announced that CEO Dr. Amit Kumar will present at the 2020 H.C. Wainwright Global Investment Conference from September 14-16, 2020. The presentation on September 16 at 10:00 a.m. ET will showcase the company's recent achievements in developing therapies against Covid-19 and its breast cancer vaccine and CAR-T based ovarian cancer programs. Interested parties can access the presentation here.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the identification of 26 new compounds targeting the main protease (Mpro) related to COVID-19, in collaboration with OntoChem. This follows the initial discovery of four compounds aimed at an endoribonuclease over four months. Anixa developed a library of over 8,000 chemicals, narrowing it down through machine learning to 317 candidates, ultimately leading to the 26 selected for synthesis and further testing. The company is preparing to file a U.S. provisional patent for these novel compounds.
